CO2019007531A2 - 3-hidroxibutirato solo o en combinación para su uso en el tratamiento de cuidados intensivos - Google Patents

3-hidroxibutirato solo o en combinación para su uso en el tratamiento de cuidados intensivos

Info

Publication number
CO2019007531A2
CO2019007531A2 CONC2019/0007531A CO2019007531A CO2019007531A2 CO 2019007531 A2 CO2019007531 A2 CO 2019007531A2 CO 2019007531 A CO2019007531 A CO 2019007531A CO 2019007531 A2 CO2019007531 A2 CO 2019007531A2
Authority
CO
Colombia
Prior art keywords
combination
critical
intensive care
care treatment
critical illness
Prior art date
Application number
CONC2019/0007531A
Other languages
English (en)
Inventor
Chloë Goossens
Lies Langouche
Den Berghe Greet Van
Ilse Vanhorebeek
Original Assignee
Univ Leuven Kath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2017/081394 external-priority patent/WO2018114309A1/en
Application filed by Univ Leuven Kath filed Critical Univ Leuven Kath
Publication of CO2019007531A2 publication Critical patent/CO2019007531A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

RESUMEN Esta invención se refiere generalmente a métodos y composiciones para el tratamiento o prevención de miopatía por enfermedades graves y polineuropatía por enfermedad crítica y de la miopatía por enfermedades graves y polineuropatía por enfermedad crítica causada por enfermedades críticas que incluyen sepsis, sepsis crítica, sepsis crítica con choque séptico, y particularmente al uso de una combinación de suministro parenteral o enteral con un 3-hidroxibutirato.
CONC2019/0007531A 2016-12-23 2019-07-15 3-hidroxibutirato solo o en combinación para su uso en el tratamiento de cuidados intensivos CO2019007531A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662438771P 2016-12-23 2016-12-23
LU100353 2017-08-01
PCT/EP2017/081394 WO2018114309A1 (en) 2016-12-23 2017-12-04 3-hydroxybutyrate alone or in combination for use in the treatment of critical care treatment

Publications (1)

Publication Number Publication Date
CO2019007531A2 true CO2019007531A2 (es) 2020-01-17

Family

ID=60582587

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0007531A CO2019007531A2 (es) 2016-12-23 2019-07-15 3-hidroxibutirato solo o en combinación para su uso en el tratamiento de cuidados intensivos

Country Status (10)

Country Link
US (2) US20190314307A1 (es)
EP (1) EP3558291A1 (es)
JP (1) JP7174428B2 (es)
KR (1) KR20190099469A (es)
CN (1) CN110248652B (es)
AU (1) AU2017381059B2 (es)
BR (1) BR112019012899A2 (es)
CA (1) CA3047362A1 (es)
CO (1) CO2019007531A2 (es)
MX (1) MX2019007597A (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11666548B2 (en) 2020-06-05 2023-06-06 Baxter International Inc. Parenteral nutrition formulation
CN117243939A (zh) * 2023-11-14 2023-12-19 南京今冉生物新材料科技有限公司 一种酮体缓释物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1098655B1 (en) * 1998-07-22 2004-11-24 Metabolix, Inc. Nutritional and therapeutic uses of 3-hydroxyalkanoate oligomers
CN1273129C (zh) * 1998-09-15 2006-09-06 英国技术集团国际有限公司 治疗组合物(ⅱ)
ES2670413T3 (es) * 2003-06-03 2018-05-30 The United States Government As Represented By The Department Of Health And Human Services Suplementos nutricionales y composiciones terapéuticas que comprenden derivados de (R)-3-hidroxibutirato
CN100344280C (zh) * 2005-08-01 2007-10-24 清华大学 3－羟基丁酸及其衍生物的新用途
EP2328858B1 (en) * 2008-08-21 2017-10-11 Oxford University Innovation Limited Drink comprising hydroxybutyrate ester and medical use thereof
GB201206192D0 (en) * 2012-04-05 2012-05-23 Tdeltas Ltd Ketone bodies and ketone body esters and for maintaining or improving muscle power output
GB201314127D0 (en) * 2013-08-07 2013-09-18 Tdeltas Ltd Ketone body and ketone body ester for reducing muscle breakdown

Also Published As

Publication number Publication date
AU2017381059B2 (en) 2023-11-30
US20190314307A1 (en) 2019-10-17
MX2019007597A (es) 2019-12-19
US20230310353A1 (en) 2023-10-05
CN110248652A (zh) 2019-09-17
KR20190099469A (ko) 2019-08-27
EP3558291A1 (en) 2019-10-30
CN110248652B (zh) 2023-05-26
JP2020502202A (ja) 2020-01-23
CA3047362A1 (en) 2018-06-28
BR112019012899A2 (pt) 2019-12-03
AU2017381059A1 (en) 2019-07-25
JP7174428B2 (ja) 2022-11-17

Similar Documents

Publication Publication Date Title
CO2018013557A2 (es) Composiciones que comprenden cepas bacterianas
CO2018010459A2 (es) Composiciones que comprenden cepas bacterianas
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CL2018001358A1 (es) Composiciones que comprenden cepas bacterianas
CR20160418A (es) Nuevos compuestos biciclicos de 7 eslabones
CL2017003142A1 (es) Composiciones que comprenden cepas bacterianas
DOP2017000097A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
CL2016002971A1 (es) Combinación.
CL2013003019A1 (es) Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih.
CL2015001756A1 (es) Compuestos derivados de carbamoilpiridona policiclicos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion de vih en un humano que tiene o se encuentra en riesgo de tener la infeccion.
CL2015003135A1 (es) Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimorficas y métodos de uso.
CL2017000533A1 (es) Pirrolopirimidinas para uso en la infección por el virus de la gripe
CL2013002898A1 (es) Compuestos derivados de benceno sustituido con arilo o heteroarilo; composicion farmaceutica que los comprende y uso en el tratamiento del cancer.
GT201200339A (es) Compuestos, composiciones de tioacetato y mètodos de uso
AR100498A1 (es) Mejora en la reducción de la fricción
BR112017000024A2 (pt) composição para tratamento de tecidos que compreende uma nanoemulsão polimérica de aminossiloxano
CL2017002031A1 (es) Formulación en polvo nasal para el tratamiento de hipoglicemia
CL2016000009A1 (es) Tratamiento de rosacea papulopustular con ivermectina.
CL2014003429A1 (es) Compuestos especificos derivados de indanosulfamida; composicion farmaceutica que los comprende, utiles en el tratamiento e la epilepsia.
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
CL2019003670A1 (es) Composición que comprende manosa oligosacárido y proceso para realizarla y uso de esta.
CL2016002151A1 (es) Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico
CL2016001210A1 (es) Análogos de bicalutamida o (s)- bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis.
UY34575A (es) Composiciones y métodos para el tratamiento de diabetes y/u obesidad
CO2019007531A2 (es) 3-hidroxibutirato solo o en combinación para su uso en el tratamiento de cuidados intensivos